Related references
Note: Only part of the references are listed.COX-mediated endothelium-dependent contractions: from the past to recent discoveries
Michael Sze-Ka Wong et al.
ACTA PHARMACOLOGICA SINICA (2010)
Predominance of cyclooxygenase 1 over cyclooxygenase 2 in the generation of proinflammatory prostaglandins in autoantibody-driven K/BxN serum-transfer arthritis
Mei Chen et al.
ARTHRITIS AND RHEUMATISM (2008)
Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction
Daniela Fraccarollo et al.
CIRCULATION (2008)
Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology
Hed Harizi et al.
TRENDS IN MOLECULAR MEDICINE (2008)
A role for the thromboxane receptor in L-NAME hypertension
Helene Francois et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2008)
Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting
Youfei Guan et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Endothelium-dependent vascular responses induced by leukotriene B4
Magnus Back et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2007)
Cyclooxygenase-1 deficiency in bone marrow cells increases early atherosclerosis in apolipoprotein E- and low-density lipoprotein receptor-null mice
VR Babaev et al.
CIRCULATION (2006)
Acetylcholine causes endothelium-dependent contraction of mouse arteries
YB Zhou et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2005)
Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women - The EPIC-Norfolk Prospective Population study
SM Boekholdt et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Cyclooxygenases, thromboxane, and atherosclerosis -: Plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism
KM Egan et al.
CIRCULATION (2005)
Glibenclamide inhibits thromboxane-mediated vasoconstriction by thromboxane receptor blockade
SL Pfister et al.
VASCULAR PHARMACOLOGY (2004)
Critical role of macrophage 12/15-lipoxygenase for atherosclerosis in apolipoprotein E-deficient mice
YQ Huo et al.
CIRCULATION (2004)
Inhibition of leukotriene synthesis with MK-886 prevents a rise in blood pressure and reduces noradrenaline-evoked contraction in L-NAME-treated rats
F Stanke-Labesque et al.
BRITISH JOURNAL OF PHARMACOLOGY (2003)
Deletion of cytosolic phospholipase A2 promotes striated muscle growth
S Haq et al.
NATURE MEDICINE (2003)
Cytosolic phospholipase A2α-deficient mice are resistant to collagen-induced arthritis
M Hegen et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Inhibition of COX-2 prevents hypertension and proteinuria associated with a decrease of 8-iso-PGF2α formation in L-NAME-treated rats
T Tomida et al.
JOURNAL OF HYPERTENSION (2003)
Development of heart failure and congenital septal defects in mice lacking endothelial nitric oxide synthase
QP Feng et al.
CIRCULATION (2002)
Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice
M Mehrabian et al.
CIRCULATION RESEARCH (2002)
A pivotal role of cytosolic phospholipase A2 in bleomycin-induced pulmonary fibrosis
T Nagase et al.
NATURE MEDICINE (2002)
Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice
ME Burleigh et al.
CIRCULATION (2002)
Risk of cardiovascular events associated with selective COX-2 inhibitors
D Mukherjee et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Cysteinyl leukotrienes are involved in angiotensin II-induced contraction of aorta from spontaneously hypertensive rats
F Stanke-Labesque et al.
CARDIOVASCULAR RESEARCH (2001)
Acute lung injury by sepsis and acid aspiration:: a key role for cytosolic phospholipase A2
T Nagase et al.
NATURE IMMUNOLOGY (2000)
Enhanced atherosclerosis and kidney dysfunction in eNOS-/-Apo-/- mice are ameliorated by enalapril treatment
JW Knowles et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)